The focus of this review is to discuss the current knowledge and recent advances regarding immune checkpoints during sepsis, and the future potential for novel immune checkpoints inhibitors, such as anti-PD1, anti-PD-L1 and anti-CTLA-4, as immunotherapeutic agents for restoring host immune response during sepsis. This evidence concerns the gene PDCD1 and Sepsis.